Clinical Trials Sponsored by Merck+Sharp+%26+Dohme+LLC

Total 3962 results

Merck Sharp & Dohme LLC

Completed

Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

Pyelonephritis | Complicated Urinary Tract Infection | Urinary Tract Infection (UTI) | Uncomplicated Pyelonephritis
Merck Sharp & Dohme LLC

Completed

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Measles | Hepatitis A | Rubella | Mumps | Chickenpox
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Merck Sharp & Dohme LLC

Terminated

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Neoplasms, Advanced
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

Type 1 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

Prevention of : Herpes-Zoster
Merck Sharp & Dohme LLC

Terminated

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

COPD
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
Merck Sharp & Dohme LLC

Completed

Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)

Hypertension
Merck Sharp & Dohme LLC

Terminated

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Overactive Bladder | Overactive Urinary Bladder
Merck Sharp & Dohme LLC

Completed

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Human Papillomavirus Infection
Merck Sharp & Dohme LLC

Completed

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Genital Warts | Cervical Cancers | Vulvar Cancers | Vaginal Cancers
Merck Sharp & Dohme LLC

Completed

Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

Rotavirus Gastroenteritis
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Pneumococcal Disease
Merck Sharp & Dohme LLC

Completed

Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

Migraine
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

Pharmacokinetics
Merck Sharp & Dohme LLC

Completed

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

Vascular Diseases | Peripheral Vascular Diseases | Migraine Disorders | Heart Disease | Cerebrovascular Accident | TIA (Transient Ischemic Attack)
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)

Dementia | Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)

Migraine
Merck Sharp & Dohme LLC

Terminated

Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718) (OD-H)

Alcoholism
Merck Sharp & Dohme LLC

Terminated

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

Lung Diseases | Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) (RUBY)

Insomnia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

Renal Insufficiency | Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

Chronic Hepatitis C Virus
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Completed

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)

Post-operative Nausea | Post-operative Vomiting
Merck Sharp & Dohme LLC

Completed

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (KMEC)

Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

Herpes Zoster | Shingles
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Chronic Hepatitis C

3

Subscribe